Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 2 Cumulative incidence of hospitalization for congestive heart failure stratified into four groups: 1) patients with normal baseline levels of B-type natriuretic peptide (BNP) (<80 ng/l) on atorvastatin; 2) patients with normal BNP on pravastatin; 3) patients with elevated levels of BNP (>80 ng/l) on atorvastatin; and 4) patients with elevated BNP on pravastatin. Comparisons between groups were performed using a Cox proportional hazard model that included age, gender, diabetes mellitus, hypertension, smoking, body mass index, creatinine, index event, percutaneous coronary intervention for index event. Among patients with elevated levels of BNP, treatment with atorvastatin significantly reduced the risk of heart failure. *Hazard ratio (HR) 6.9, 95% confidence interval (CI) 3.3 to 14.4, p < 0.001 compared with BNP <80/atorvastatin; **HR 2.2, 95% CI 0.85 to 5.9, p = 0.115 compared with BNP <80/atorvastatin; ***HR 1.7, 95% CI 0.90 to 3.4, p = 0.099 compared with BNP <80/atorvastatin;  HR 0.32, 95% CI 0.13 to 0.8, p = 0.014 compared with BNP >80/pravastatin.
|
